O-022Phase II study evaluating trifluridine/tipiracil +...

Annals of Oncology 2018 / 06 Vol. 29; Iss. suppl_5

O-022Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis

Lesniewski-Kmak, K, Moiseenko, V, Saunders, M, Wasan, H, Argiles, G, Borg, C, Creemers, G, Fedyanin, M, Glynne-Jones, R, Pfeiffer, P, Punt, C, Stroyakovskiy, D, Ten Tije, A, Van de Wouw, A, Kanehisa,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy149.021
Date:
June, 2018
File:
PDF, 49 KB
english, 2018
Conversion to is in progress
Conversion to is failed